Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas

Neuropathol Appl Neurobiol. 1998 Dec;24(6):434-40. doi: 10.1046/j.1365-2990.1998.00143.x.

Abstract

Conventional histological evaluation and subclassification of childhood ependymomas poorly predict their biological behaviour. The Ki-67 labelling index (Ki-67 LI), a measure of growth fraction, correlates with the biological behaviour of several neoplasms, and this retrospective study tested the hypothesis that Ki-67 LI is a prognostic indicator in childhood posterior fossa ependymomas. Immunocytochemistry using an antibody to Ki-67 was undertaken on 5 microns sections of formalin-fixed, paraffin-embedded tissue from 74 cases of childhood (age < 16 years.) posterior fossa ependymoma. A Ki-67 LI was established by counting the proportion of labelled nuclei in more than 1000 cells from several histological fields. Several clinical and histological variables (including Ki-67 LI) potentially associated with survival were entered into univariate and multivariate analyses using a Cox proportional hazards model. Variables that showed a significant and independent association with survival were Ki-67 LI (P < 0.002), whether total surgical resection had been achieved according to operation records (P < 0.03), and whether no adjuvant therapy had been given (P < 0.01). Age, sex, and the presence of necrosis or microvascular proliferation did not correlate with survival. In our defined population of patients with ependymomas, Ki-67 LI is a strong prognostic indicator. We recommend that Ki-67 LI is used in the histological evaluation of childhood posterior fossa ependymomas during trials of novel adjunctive therapies.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Cranial Fossa, Posterior*
  • Ependymoma / immunology*
  • Ependymoma / mortality
  • Female
  • Humans
  • Immunohistochemistry
  • Infant
  • Ki-67 Antigen / analysis*
  • Male
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Skull Base Neoplasms / immunology*
  • Skull Base Neoplasms / mortality
  • Survival Rate

Substances

  • Ki-67 Antigen